Literature DB >> 29519805

Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma.

Yi Jin1, Kenian Chen1, Ayla De Paepe2, Eva Hellqvist2, Aleksandra D Krstic2, Lauren Metang1, Charlotte Gustafsson2, Richard E Davis3, Yair M Levy4, Rakesh Surapaneni5, Ann Wallblom2, Hareth Nahi6, Robert Mansson2,6, Yin C Lin1.   

Abstract

Multiple myeloma (MM) is an aggressive cancer that originates from antibody-secreting plasma cells. Although genetically and transcriptionally well characterized, the aberrant gene regulatory networks that underpin this disease remain poorly understood. Here, we mapped regulatory elements, open chromatin, and transcription factor (TF) footprints in primary MM cells. In comparison with normal antibody-secreting cells, MM cells displayed consistent changes in enhancer activity that are connected to superenhancer (SE)-mediated deregulation of TF genes. MM cells also displayed widespread decompaction of heterochromatin that was associated with activation of regulatory elements and in a major subset of patients' deregulation of the cyclic adenosine monophosphate pathway. Finally, building SE-associated TF-based regulatory networks allowed identification of several novel TFs that are central to MM biology. Taken together, these findings significantly add to our understanding of the aberrant gene regulatory network that underpins MM.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29519805      PMCID: PMC6014038          DOI: 10.1182/blood-2017-09-808063

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  47 in total

1.  Super-enhancers in the control of cell identity and disease.

Authors:  Denes Hnisz; Brian J Abraham; Tong Ihn Lee; Ashley Lau; Violaine Saint-André; Alla A Sigova; Heather A Hoke; Richard A Young
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

2.  Transcriptional amplification in tumor cells with elevated c-Myc.

Authors:  Charles Y Lin; Jakob Lovén; Peter B Rahl; Ronald M Paranal; Christopher B Burge; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2012-09-28       Impact factor: 41.582

3.  Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells.

Authors:  Alejo A Morales; Metin Kurtoglu; Shannon M Matulis; Jiangxia Liu; David Siefker; Delia M Gutman; Jonathan L Kaufman; Kelvin P Lee; Sagar Lonial; Lawrence H Boise
Journal:  Blood       Date:  2011-06-09       Impact factor: 22.113

4.  A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression.

Authors:  Christina M Annunziata; Lidia Hernandez; R Eric Davis; Adriana Zingone; Laurence Lamy; Lloyd T Lam; Elaine M Hurt; Arthur L Shaffer; W Michael Kuehl; Louis M Staudt
Journal:  Blood       Date:  2010-12-16       Impact factor: 22.113

5.  Selective inhibition of tumor oncogenes by disruption of super-enhancers.

Authors:  Jakob Lovén; Heather A Hoke; Charles Y Lin; Ashley Lau; David A Orlando; Christopher R Vakoc; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2013-04-11       Impact factor: 41.582

6.  A global network of transcription factors, involving E2A, EBF1 and Foxo1, that orchestrates B cell fate.

Authors:  Yin C Lin; Suchit Jhunjhunwala; Christopher Benner; Sven Heinz; Eva Welinder; Robert Mansson; Mikael Sigvardsson; James Hagman; Celso A Espinoza; Janusz Dutkowski; Trey Ideker; Christopher K Glass; Cornelis Murre
Journal:  Nat Immunol       Date:  2010-06-13       Impact factor: 25.606

7.  Blimp1 is limiting for transformation in a mouse plasmacytoma model.

Authors:  Kathy D'Costa; Dianne Emslie; Donald Metcalf; Gordon K Smyth; Alexander Karnowski; Axel Kallies; Stephen L Nutt; Lynn M Corcoran
Journal:  Blood       Date:  2009-03-27       Impact factor: 22.113

8.  DNase footprint signatures are dictated by factor dynamics and DNA sequence.

Authors:  Myong-Hee Sung; Michael J Guertin; Songjoon Baek; Gordon L Hager
Journal:  Mol Cell       Date:  2014-09-18       Impact factor: 17.970

9.  The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis.

Authors:  Daniel R Carrasco; Kumar Sukhdeo; Marina Protopopova; Raktim Sinha; Miriam Enos; Daniel E Carrasco; Mei Zheng; Mala Mani; Joel Henderson; Geraldine S Pinkus; Nikhil Munshi; James Horner; Elena V Ivanova; Alexei Protopopov; Kenneth C Anderson; Giovanni Tonon; Ronald A DePinho
Journal:  Cancer Cell       Date:  2007-04       Impact factor: 31.743

10.  Integrative analysis of 111 reference human epigenomes.

Authors:  Anshul Kundaje; Wouter Meuleman; Jason Ernst; Misha Bilenky; Angela Yen; Alireza Heravi-Moussavi; Pouya Kheradpour; Zhizhuo Zhang; Jianrong Wang; Michael J Ziller; Viren Amin; John W Whitaker; Matthew D Schultz; Lucas D Ward; Abhishek Sarkar; Gerald Quon; Richard S Sandstrom; Matthew L Eaton; Yi-Chieh Wu; Andreas R Pfenning; Xinchen Wang; Melina Claussnitzer; Yaping Liu; Cristian Coarfa; R Alan Harris; Noam Shoresh; Charles B Epstein; Elizabeta Gjoneska; Danny Leung; Wei Xie; R David Hawkins; Ryan Lister; Chibo Hong; Philippe Gascard; Andrew J Mungall; Richard Moore; Eric Chuah; Angela Tam; Theresa K Canfield; R Scott Hansen; Rajinder Kaul; Peter J Sabo; Mukul S Bansal; Annaick Carles; Jesse R Dixon; Kai-How Farh; Soheil Feizi; Rosa Karlic; Ah-Ram Kim; Ashwinikumar Kulkarni; Daofeng Li; Rebecca Lowdon; GiNell Elliott; Tim R Mercer; Shane J Neph; Vitor Onuchic; Paz Polak; Nisha Rajagopal; Pradipta Ray; Richard C Sallari; Kyle T Siebenthall; Nicholas A Sinnott-Armstrong; Michael Stevens; Robert E Thurman; Jie Wu; Bo Zhang; Xin Zhou; Arthur E Beaudet; Laurie A Boyer; Philip L De Jager; Peggy J Farnham; Susan J Fisher; David Haussler; Steven J M Jones; Wei Li; Marco A Marra; Michael T McManus; Shamil Sunyaev; James A Thomson; Thea D Tlsty; Li-Huei Tsai; Wei Wang; Robert A Waterland; Michael Q Zhang; Lisa H Chadwick; Bradley E Bernstein; Joseph F Costello; Joseph R Ecker; Martin Hirst; Alexander Meissner; Aleksandar Milosavljevic; Bing Ren; John A Stamatoyannopoulos; Ting Wang; Manolis Kellis
Journal:  Nature       Date:  2015-02-19       Impact factor: 69.504

View more
  28 in total

1.  Che-1/AATF-induced transcriptionally active chromatin promotes cell proliferation in multiple myeloma.

Authors:  Tiziana Bruno; Francesca De Nicola; Giacomo Corleone; Valeria Catena; Frauke Goeman; Matteo Pallocca; Cristina Sorino; Gianluca Bossi; Bruno Amadio; Giovanni Cigliana; Maria Rosaria Ricciardi; Maria Teresa Petrucci; Enrico Pierluigi Spugnini; Alfonso Baldi; Mario Cioce; Giancarlo Cortese; Elisabetta Mattei; Roberta Merola; Umberto Gianelli; Luca Baldini; Francesco Pisani; Svitlana Gumenyuk; Andrea Mengarelli; Katja Höpker; Thomas Benzing; Bruno Vincenzi; Aristide Floridi; Claudio Passananti; Giovanni Blandino; Simona Iezzi; Maurizio Fanciulli
Journal:  Blood Adv       Date:  2020-11-24

2.  FOXO1 and FOXO3 Cooperatively Regulate Innate Lymphoid Cell Development.

Authors:  Thuy T Luu; Jonas Nørskov Søndergaard; Lucía Peña-Pérez; Shabnam Kharazi; Aleksandra Krstic; Stephan Meinke; Laurent Schmied; Nicolai Frengen; Yaser Heshmati; Marcin Kierczak; Thibault Bouderlique; Arnika Kathleen Wagner; Charlotte Gustafsson; Benedict J Chambers; Adnane Achour; Claudia Kutter; Petter Höglund; Robert Månsson; Nadir Kadri
Journal:  Front Immunol       Date:  2022-06-09       Impact factor: 8.786

Review 3.  Chromosome Territories in Hematological Malignancies.

Authors:  Matheus Fabiao de Lima; Mateus de Oliveira Lisboa; Lucas E L Terceiro; Aline Rangel-Pozzo; Sabine Mai
Journal:  Cells       Date:  2022-04-17       Impact factor: 7.666

4.  Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma.

Authors:  Paula M Vertino; Lawrence H Boise; Benjamin G Barwick; Vikas A Gupta; Shannon M Matulis; Jonathan C Patton; Doris R Powell; Yanyan Gu; David L Jaye; Karen N Conneely; Yin C Lin; Craig C Hofmeister; Ajay K Nooka; Jonathan J Keats; Sagar Lonial
Journal:  Clin Cancer Res       Date:  2021-03-17       Impact factor: 12.531

Review 5.  Functions and Clinical Significance of Super-Enhancers in Bone-Related Diseases.

Authors:  Jian Qu; Zhanbo Ouyang; Wenqiang Wu; Guohua Li; Jiaojiao Wang; Qiong Lu; Zhihong Li
Journal:  Front Cell Dev Biol       Date:  2020-06-30

Review 6.  Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis.

Authors:  Daniel Heudobler; Michael Rechenmacher; Florian Lüke; Martin Vogelhuber; Sebastian Klobuch; Simone Thomas; Tobias Pukrop; Christina Hackl; Wolfgang Herr; Lina Ghibelli; Christopher Gerner; Albrecht Reichle
Journal:  Front Pharmacol       Date:  2018-11-28       Impact factor: 5.810

Review 7.  Germline Risk Contribution to Genomic Instability in Multiple Myeloma.

Authors:  Siegfried Janz; Fenghuang Zhan; Fumou Sun; Yan Cheng; Michael Pisano; Ye Yang; Hartmut Goldschmidt; Parameswaran Hari
Journal:  Front Genet       Date:  2019-05-08       Impact factor: 4.599

8.  The DNA methylation landscape of multiple myeloma shows extensive inter- and intrapatient heterogeneity that fuels transcriptomic variability.

Authors:  Jennifer Derrien; Catherine Guérin-Charbonnel; Victor Gaborit; Loïc Campion; Magali Devic; Elise Douillard; Nathalie Roi; Hervé Avet-Loiseau; Olivier Decaux; Thierry Facon; Jan-Philipp Mallm; Roland Eils; Nikhil C Munshi; Philippe Moreau; Carl Herrmann; Florence Magrangeas; Stéphane Minvielle
Journal:  Genome Med       Date:  2021-08-09       Impact factor: 11.117

9.  Revealing the impact of structural variants in multiple myeloma.

Authors:  Ola Landgren; Francesco Maura; Even H Rustad; Venkata D Yellapantula; Dominik Glodzik; Kylee H Maclachlan; Benjamin Diamond; Eileen M Boyle; Cody Ashby; Patrick Blaney; Gunes Gundem; Malin Hultcrantz; Daniel Leongamornlert; Nicos Angelopoulos; Luca Agnelli; Daniel Auclair; Yanming Zhang; Ahmet Dogan; Niccolò Bolli; Elli Papaemmanuil; Kenneth C Anderson; Philippe Moreau; Hervé Avet-Loiseau; Nikhil C Munshi; Jonathan J Keats; Peter J Campbell; Gareth J Morgan
Journal:  Blood Cancer Discov       Date:  2020-09-15

Review 10.  Super-enhancer-mediated core regulatory circuitry in human cancer.

Authors:  Yuan Jiang; Yan-Yi Jiang; De-Chen Lin
Journal:  Comput Struct Biotechnol J       Date:  2021-05-05       Impact factor: 7.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.